Supernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 5.7% – Here’s Why

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s share price traded down 5.7% during mid-day trading on Monday . The stock traded as low as $36.41 and last traded at $36.19. 266,106 shares traded hands during trading, a decline of 18% from the average session volume of 324,345 shares. The stock had previously closed at $38.37.

Analyst Ratings Changes

SUPN has been the subject of a number of analyst reports. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Cantor Fitzgerald assumed coverage on Supernus Pharmaceuticals in a research note on Monday, January 6th. They issued an “overweight” rating and a $57.00 price target on the stock. Finally, Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

The firm’s fifty day simple moving average is $37.24 and its 200 day simple moving average is $34.66. The company has a market capitalization of $2.18 billion, a PE ratio of 36.90 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. Supernus Pharmaceuticals’s quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.29) EPS. On average, equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current fiscal year.

Insider Activity

In related news, CEO Jack A. Khattar sold 125,000 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the completion of the sale, the chief executive officer now directly owns 926,172 shares in the company, valued at approximately $33,971,988.96. The trade was a 11.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 700 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 164,390 shares of company stock worth $6,064,151. 9.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC raised its holdings in Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 398 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 870 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Supernus Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 352 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $72,000. Finally, Venturi Wealth Management LLC acquired a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $92,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.